Please login to the form below

Not currently logged in
Email:
Password:

ThromboGenics

This page shows the latest ThromboGenics news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug. Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction. ... progressive disease much earlier and as soon as patients start experiencing symptoms such as

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    ThromboGenics bolsters leadership team. Appoints Susan Schneider as CMO and Vinciane Vangeersdaele as CCO. ... Patrik De Haes, chief executive officer, ThromboGenics, said: “We are very pleased to welcome Susan and Vinciane to the company.

  • ThromoboGenics appoints Thomas Clay as chairman of the board ThromoboGenics appoints Thomas Clay as chairman of the board

    Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf Van Reet, who retires. ... Clay has been a non-executive director of ThromboGenics since 2011 when he replaced his

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics